What are the uses of Pazopanib Hydrochloride?

Pazopanib Hydrochloride is a novel oral, potent and highly selective multi-target multi-protein tyrosine kinase small molecule inhibitor with potential anti-tumor activity. Developed by GlaxoSmithKline, it was approved by the FDA on October 19, 2009 for the treatment of renal cell carcinoma. It can also be used for patients with advanced soft tissue sarcoma (STS) who have previously received chemotherapy, platinum-resistant or platinum-refractory epithelial ovarian cancer, and maintenance treatment of non-small cell lung cancer (NSCLC) after first-line chemotherapy.

Pazopanib Hydrochloride can inhibit multiple targets such as VEGFR-1, VEGFR-2 and VEGFR-3 that regulate angiogenesis, PDGFR-α and PDGFR-β that regulate angiogenesis and proliferation of certain tumor cells, and c-Kit intracellular tyrosine kinase that regulates cell proliferation and survival.

Clinical studies have shown that pazopanib has significant efficacy in renal cell carcinoma, and safety study results also show that patients tolerate it well. The drug provides a new option for the treatment of advanced renal cell carcinoma.

Indications

Renal cell carcinoma: Pazopanib Hydrochloride can be used for the first-line treatment of advanced renal cell carcinoma or patients with advanced renal cell carcinoma who have received cytokine therapy.

Soft tissue sarcoma: It is used to treat patients with certain subtypes of advanced soft tissue sarcoma, especially those who have previously received chemotherapy or have received other adjuvant therapy but whose disease has worsened within one year. Maintenance treatment of platinum-resistant or platinum-refractory epithelial ovarian cancer and non-small cell lung cancer (NSCLC) after first-line chemotherapy.

Recommended dosage

The recommended dose is 800 mg once a day. If a dose is missed and the next dose is less than 12 hours away, it should not be taken.

Adverse reactions

The most common adverse reactions (≥20%) of Pazopanib Hydrochloride are diarrhea, hypertension, hair color changes (depigmentation), nausea, anorexia, and vomiting.

You may like